Literature DB >> 22343495

Cognitive changes associated with ADT: a review of the literature.

Rhoda J Jamadar1, Mary J Winters, Pauline M Maki.   

Abstract

The use of androgen deprivation therapy (ADT) has increased since the early 1990s after early detection efforts and greater use of the prostate-specific antigen (PSA) test. Although ADT is associated with favorable clinical outcomes, ADT has been associated with an increased risk for cardiovascular disease, increased serum cholesterol, triglycerides, insulin resistance, body mass index and fat body mass. Here we review findings from 11 clinical studies examining the effects of ADT on cognition as measured by standardized tests in cognitive domains such as verbal and spatial memory. Most of these studies have important limitations, including small sample sizes, suboptimal control groups and baseline group differences in confounding factors. Despite these limitations, the best designed studies, those comparing patients on ADT to healthy controls, generally suggest that spatial memory might be especially sensitive to the effects of ADT. Critically, to date there is only one study involving random assignment of ADT versus close clinical observation. That study revealed a decrease in verbal memory with ADT, but was limited in sample size and did not include a measure of spatial memory. A recent observational study revealed no substantial evidence of cognitive impairment with ADT, even in the domain of verbal memory. Like the randomized study, however, this large observational study lacked a measure of spatial memory. Overall, the studies with the best controls suggest a potential negative impact of ADT on spatial memory, and perhaps verbal memory, and a need for continued investigation of the impact of ADT on cognition, particularly in these two cognitive domains.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343495      PMCID: PMC3735092          DOI: 10.1038/aja.2011.107

Source DB:  PubMed          Journal:  Asian J Androl        ISSN: 1008-682X            Impact factor:   3.285


  53 in total

1.  Sex steroids modify working memory.

Authors:  J S Janowsky; B Chavez; E Orwoll
Journal:  J Cogn Neurosci       Date:  2000-05       Impact factor: 3.225

2.  Serum total testosterone is lower in men with Alzheimer's disease.

Authors:  E Hogervorst; J Williams; M Budge; L Barnetson; M Combrinck; A D Smith
Journal:  Neuro Endocrinol Lett       Date:  2001-06       Impact factor: 0.765

3.  Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?

Authors:  Mathis Grossmann; Jeffrey D Zajac
Journal:  Clin Endocrinol (Oxf)       Date:  2011-03       Impact factor: 3.478

4.  Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer.

Authors:  Shabbir M H Alibhai; Henriette Breunis; Narhari Timilshina; Shireen Marzouk; Diane Stewart; Ian Tannock; Gary Naglie; George Tomlinson; Neil Fleshner; Murray Krahn; Padraig Warde; Sarah Duff Canning
Journal:  J Clin Oncol       Date:  2010-11-01       Impact factor: 44.544

5.  Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging.

Authors:  S M Harman; E J Metter; J D Tobin; J Pearson; M R Blackman
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

6.  Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer.

Authors:  Philip J Saylor; Matthew R Smith
Journal:  J Natl Compr Canc Netw       Date:  2010-02       Impact factor: 11.908

7.  Effects of transdermal testosterone on cognitive function and health perception in older men with low bioavailable testosterone levels.

Authors:  Anne M Kenny; Sandra Bellantonio; Cynthia A Gruman; Ruben D Acosta; Karen M Prestwood
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2002-05       Impact factor: 6.053

8.  Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study.

Authors:  Henry A Feldman; Christopher Longcope; Carol A Derby; Catherine B Johannes; Andre B Araujo; Andrea D Coviello; William J Bremner; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

9.  Testosterone supplementation improves spatial and verbal memory in healthy older men.

Authors:  M M Cherrier; S Asthana; S Plymate; L Baker; A M Matsumoto; E Peskind; M A Raskind; K Brodkin; W Bremner; A Petrova; S LaTendresse; S Craft
Journal:  Neurology       Date:  2001-07-10       Impact factor: 9.910

10.  Changes in neuronal activation patterns in response to androgen deprivation therapy: a pilot study.

Authors:  Monique M Cherrier; Paul R Borghesani; Amy L Shelton; Celestia S Higano
Journal:  BMC Cancer       Date:  2010-01-04       Impact factor: 4.430

View more
  22 in total

1.  Time to raise awareness regarding complications of androgen deprivation therapy.

Authors:  Shehzad Basaria
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

Review 2.  Memory and cancer: a review of the literature.

Authors:  Graham J McDougall; JoAnn S Oliver; Forrest Scogin
Journal:  Arch Psychiatr Nurs       Date:  2014-03-22       Impact factor: 2.218

Review 3.  Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis.

Authors:  Heather L McGinty; Kristin M Phillips; Heather S L Jim; Julie M Cessna; Yasmin Asvat; Mallory G Cases; Brent J Small; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2014-05-25       Impact factor: 3.603

Review 4.  Cognitive impairment following hormone therapy: current opinion of research in breast and prostate cancer patients.

Authors:  Lisa M Wu; Ali Amidi
Journal:  Curr Opin Support Palliat Care       Date:  2017-03       Impact factor: 2.302

5.  Cognitive problems in patients on androgen deprivation therapy: a qualitative pilot study.

Authors:  Lisa M Wu; Michael A Diefenbach; Wayne A Gordon; Joshua B Cantor; Monique M Cherrier
Journal:  Urol Oncol       Date:  2012-09-10       Impact factor: 3.498

Review 6.  Cognitive effects of cancer systemic therapy: implications for the care of older patients and survivors.

Authors:  Jeanne S Mandelblatt; Paul B Jacobsen; Tim Ahles
Journal:  J Clin Oncol       Date:  2014-07-28       Impact factor: 44.544

7.  Expansion of mossy fibers and CA3 apical dendritic length accompanies the fall in dendritic spine density after gonadectomy in male, but not female, rats.

Authors:  Ari L Mendell; Sarah Atwi; Craig D C Bailey; Dan McCloskey; Helen E Scharfman; Neil J MacLusky
Journal:  Brain Struct Funct       Date:  2016-06-09       Impact factor: 3.270

Review 8.  Long-term Toxicity of Cancer Treatment in Older Patients.

Authors:  Armin Shahrokni; Abraham J Wu; Jeanne Carter; Stuart M Lichtman
Journal:  Clin Geriatr Med       Date:  2015-10-13       Impact factor: 3.076

Review 9.  Androgen Deprivation Therapy and Cognitive Function in Prostate Cancer.

Authors:  Jonathan Kluger; Alicia Roy; Herta H Chao
Journal:  Curr Oncol Rep       Date:  2020-02-11       Impact factor: 5.075

10.  Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer.

Authors:  Alexandra M Sharp; Suphada Lertphinyowong; Samantha S Yee; Denisse Paredes; Jonathan Gelfond; Teresa L Johnson-Pais; Robin J Leach; Michael Liss; April L Risinger; Anna C Sullivan; Ian M Thompson; David A Morilak
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.